Dubai Telegraph - 'Remarkable' Alzheimer's drug reduces cognitive decline, study shows

EUR -
AED 3.82663
AFN 70.961809
ALL 98.138672
AMD 405.653176
ANG 1.877183
AOA 951.190967
ARS 1044.167695
AUD 1.599646
AWG 1.877898
AZN 1.768925
BAM 1.955574
BBD 2.102957
BDT 124.465633
BGN 1.955296
BHD 0.392555
BIF 3076.644867
BMD 1.04183
BND 1.403838
BOB 7.197169
BRL 6.043616
BSD 1.04158
BTN 87.914552
BWP 14.229358
BYN 3.408607
BYR 20419.862965
BZD 2.099458
CAD 1.456197
CDF 2991.093261
CHF 0.930624
CLF 0.036923
CLP 1018.831698
CNY 7.545955
CNH 7.559141
COP 4573.372102
CRC 530.538761
CUC 1.04183
CUP 27.608488
CVE 110.252274
CZK 25.306722
DJF 185.47859
DKK 7.457725
DOP 62.772754
DZD 139.835859
EGP 51.650195
ERN 15.627446
ETB 127.508482
FJD 2.371152
FKP 0.822334
GBP 0.831137
GEL 2.854575
GGP 0.822334
GHS 16.4561
GIP 0.822334
GMD 73.969495
GNF 8977.963687
GTQ 8.040072
GYD 217.904848
HKD 8.10981
HNL 26.320962
HRK 7.431641
HTG 136.724218
HUF 410.920048
IDR 16610.464601
ILS 3.856615
IMP 0.822334
INR 87.968197
IQD 1364.442504
IRR 43834.985936
ISK 145.522363
JEP 0.822334
JMD 165.930847
JOD 0.738756
JPY 161.24407
KES 134.88443
KGS 90.11281
KHR 4193.515949
KMF 492.261294
KPW 937.646374
KRW 1463.260366
KWD 0.320727
KYD 0.868
KZT 520.05997
LAK 22878.359185
LBP 93271.23384
LKR 303.145008
LRD 187.9983
LSL 18.79533
LTL 3.076253
LVL 0.630192
LYD 5.086413
MAD 10.478091
MDL 18.997807
MGA 4861.438851
MKD 61.522899
MMK 3383.822366
MNT 3540.137411
MOP 8.350936
MRU 41.443216
MUR 48.810137
MVR 16.1068
MWK 1806.091526
MXN 21.300719
MYR 4.654898
MZN 66.582998
NAD 18.79533
NGN 1767.669283
NIO 38.325576
NOK 11.541432
NPR 140.663763
NZD 1.785677
OMR 0.400944
PAB 1.04158
PEN 3.949544
PGK 4.193516
PHP 61.40439
PKR 289.239713
PLN 4.332887
PYG 8131.061444
QAR 3.798562
RON 4.980248
RSD 116.991496
RUB 108.510536
RWF 1421.83588
SAR 3.911475
SBD 8.734237
SCR 14.271984
SDG 626.658476
SEK 11.49581
SGD 1.402926
SHP 0.822334
SLE 23.680862
SLL 21846.653733
SOS 595.231293
SRD 36.978666
STD 21563.772237
SVC 9.113948
SYP 2617.628337
SZL 18.788831
THB 36.0395
TJS 11.09252
TMT 3.646404
TND 3.309018
TOP 2.440069
TRY 35.958741
TTD 7.074183
TWD 33.946456
TZS 2770.580196
UAH 43.090026
UGX 3848.555767
USD 1.04183
UYU 44.294887
UZS 13362.457591
VES 48.506696
VND 26482.270241
VUV 123.688121
WST 2.908362
XAF 655.881293
XAG 0.033274
XAU 0.000384
XCD 2.815597
XDR 0.792309
XOF 655.881293
XPF 119.331742
YER 260.379266
ZAR 18.844783
ZMK 9377.714007
ZMW 28.772679
ZWL 335.468752
  • SCS

    0.2300

    13.27

    +1.73%

  • RELX

    0.9900

    46.75

    +2.12%

  • RBGPF

    59.2400

    59.24

    +100%

  • BCC

    3.4200

    143.78

    +2.38%

  • RYCEF

    -0.0100

    6.79

    -0.15%

  • BCE

    0.0900

    26.77

    +0.34%

  • NGG

    1.0296

    63.11

    +1.63%

  • CMSC

    0.0320

    24.672

    +0.13%

  • RIO

    -0.2200

    62.35

    -0.35%

  • CMSD

    0.0150

    24.46

    +0.06%

  • GSK

    0.2600

    33.96

    +0.77%

  • JRI

    -0.0200

    13.21

    -0.15%

  • AZN

    1.3700

    65.63

    +2.09%

  • VOD

    0.1323

    8.73

    +1.52%

  • BP

    0.2000

    29.72

    +0.67%

  • BTI

    0.4000

    37.38

    +1.07%

'Remarkable' Alzheimer's drug reduces cognitive decline, study shows
'Remarkable' Alzheimer's drug reduces cognitive decline, study shows / Photo: Philippe LOPEZ - AFP/File

'Remarkable' Alzheimer's drug reduces cognitive decline, study shows

US pharmaceutical giant Eli Lilly on Wednesday announced its experimental Alzheimer's drug significantly slowed cognitive and functional decline, results hailed as "remarkable" by experts despite some patients experiencing serious side effects.

Text size:

In an analysis of nearly 1,200 people in the early stages of the disease, donanemab slowed the progression of symptoms by 35 percent over a period of 18 months compared to placebo.

This was measured by cognition and their ability to carry out daily tasks like managing finances, driving, engaging in hobbies and conversing about current events in a standardized index called the Integrated Alzheimer's Disease Rating Scale (iADRS).

Side effects included temporary swelling in parts of the brain, which occurred in almost a quarter of the treated patients, as well as microhemorrhages that occurred in 31 percent of patients on the treatment arm and 14 percent of patients in the placebo group.

Two participants' deaths were attributed to the side effects, while a third might have also died from the treatment.

Nonetheless, the data was widely praised by independent experts, who said donanemab had the potential, if approved, to significantly improve the lives of people suffering from the most common form of dementia.

The news comes after the US approved another Alzheimer's drug in January, Biogen and Eisai's lecanemab, which slowed the rate of cognitive decline by 27 percent and was also declared a blockbuster by experts.

Biogen and Eisai had also developed aducanumab, known by the trade Aduhelm, which was given US approval in 2021, though that decision was mired in controversy and led to a damning report by Congress.

In addition to severe side effects, Aduhlem's clinical effectiveness was ambiguous, which is so far not the case for the two subsequent drugs.

Lilly said it would rapidly submit its results to the US Food and Drug Administration (FDA) as well as other global regulators.

"We are extremely pleased that donanemab yielded positive clinical results with compelling statistical significance for people with Alzheimer's disease in this trial," said Daniel Skovronsky, Lilly's chief scientific and medical officer, in a statement.

Mark Mintun, a top Lilly executive in neuroscience R&D, added however that "like many effective treatments for debilitating and fatal diseases, there are associated risks that may be serious and life-threatening."

Eli Lilly's stock price rose 4.3 percent after Wednesday's announcement.

- Targeting amyloid -

In Alzheimer's disease, two key proteins, tau and amyloid beta, build up into tangles and plaques, known together as aggregates, which cause brain cells to die and lead to brain shrinkage.

Like lecanemab (also known by its trade name Leqembi), donanemab is an antibody therapy that targets amyloid beta.

Experts said that the results for both drugs validated the theory that removing amyloid beta does improve the course of the disease, and that future therapies targeting both proteins might have even better outcomes.

Nick Fox, of the UK Dementia Research Institute, said that although the full dataset was not yet available, the results announced by press release "confirms that we are in a new era of disease modification for Alzheimer's disease."

"This clinical trial is a real breakthrough, demonstrating a remarkable 35% slowing of cognitive decline in Alzheimer's patients with high amyloid beta but low tau burden," added Marc Busche, UK Dementia Research Institute group leader at University College London.

"These are the strongest phase 3 data for an Alzheimer's treatment to date," said Maria Carrillo, chief science officer at the US Alzheimer's Association. "This further underscores the inflection point we are at for the Alzheimer's field."

Alzheimer's disease accounts for 60-80 percent of dementia, according to the Alzheimer's Association. It progressively destroys thinking and memory, eventually robbing people of the ability to carry out the simplest of tasks.

G.Gopinath--DT